Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.

Last Updated: Wednesday, October 12, 2022

This study investigates several potential factors that could determine durable therapeutic response for patients with myeloma who receive BCMA CAR T-cell therapy. The authors conclude that there is a dynamic relationship among “endogenous T, CAR T, myeloid/dendritic cells, and tumor compartments” that could be further investigated regarding potentially prognostic factors.

Blood Cancer Discovery

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Frontiers in Immunology

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

Blood Advances

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Annals of Medicine

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Hematology

Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib

Hematology

Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy

Blood

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis

Blood

Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

CAR T-Cell Therapy Resource Center

Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.

Blood Advances

Local radiation enhances systemic CAR T cell efficacy by augmenting antigen cross-presentation and T-cell infiltration

Blood Advances

Feasibility and favorable responses following investigational CAR T-Cell therapy for relapsed and refractory infant ALL

Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

Frontiers in Immunology

Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: A systematic review and meta-analysis

Blood Advances

Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Annals of Medicine

Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis

Hematology

Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib

Hematology

Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy

Blood

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis

Blood

Optimizing the post-CAR T monitoring period for axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

B-Cell Aplasia, Hypogammaglobulinemia Can Result in Serious, Life-Threatening Infections

Fast Facts #12: BCMA Targets